Nuvilex Inc  

(Public, OTCMKTS:NVLX)   Watch this stock  
Find more results for PINK:NVLX
+0.004 (2.04%)
Nov 21 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.22 - 0.23
52 week 0.02 - 0.62
Open 0.22
Vol / Avg. 1.36M/1.48M
Mkt cap 156.04M
P/E     -
Div/yield     -
EPS -0.04
Shares 693.51M
Beta 0.76
Inst. own 0%

Key stats and ratios

Q3 (Jul '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -72.59% -447.04%
Return on average equity -75.81% -732.54%
Employees 4 -
CDP Score - -


Suite 310, 12510 Prosperity Drive
SILVER SPRING, MD 20904-1643
United States - Map
+1-917-5952850 (Phone)
+1-917-5952850 (Fax)

Website links


Nuvilex, Inc. operates independently and through wholly owned subsidiaries. The Company is a biotechnology and life technology company with a specialty in living-cell encapsulation. It is focused on preparations for a new pancreatic cancer clinical trial through live-cell encapsulation of chemotherapeutic-converting cells. It has created the hardware and operating platform to envelop or encapsulate its own or other company's software products, or cells. These cells are then packaged in its live cell encapsulation operating system. Its products include Cinnechol, Cinnergen, Cinnsational, Citroxin, Cyclosurface, Cosmetics, Infinitink, Talsyn, Oraphyte and PurEffect. On July 10, 2013, the Company acquired Bio Blue Bird AG. In November 2013, the Company announced that it has acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes from SG Austria Pte. Ltd.

Officers and directors

Kenneth L. Waggoner Chairman of the Board, President, Chief Executive Officer, General Counsel
Age: 65
Robert Bowker President of Knock-Out Technologies, Inc.
Age: 65
Richard M. Goldfarb M.D. President of MedElite Inc
Age: 60
Gerald W. Crabtree Ph.D. Chief Operating Officer, Director
Age: 73
Walter H. Gunzburg Chief Scientific Officer